Simcere Pharmaceutical Group (HKSE:02096) Other Financing: HK$-508 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02096 Simcere Pharmaceutical Group Ltd HKSE:02096
94 GF Score
Price HK$12.14
GF Value HK$11.03
Valuation Fairly Valued
View Full Analysis

What is Simcere Pharmaceutical Group Other Financing?

Simcere Pharmaceutical Group HKSE:02096 -0.25% 94 Other Financing is HK$-508 Mil as of Dec. 2025. GuruFocus rates HKSE:02096 with a GF Score™ of 94/100 and a GF Value™ of HK$11.03 (Fairly Valued).

Simcere Pharmaceutical Group's Other Financing for the six months ended in Dec. 2025 was HK$-560 Mil.

Simcere Pharmaceutical Group's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-508 Mil.

Simcere Pharmaceutical Group Other Financing Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Other Financing Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only 299.69 -51.38 -38.80 1,030.34 13.75

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -527.25 975.69 -462.49 52.46 -560.24
HKSE:02096
94GF Score
Simcere Pharmaceutical Group Ltd HKSE:02096
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-508 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$-508 Mil mean?
Simcere Pharmaceutical Group (HKSE:02096) has a Other Financing of HK$-508 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Other Financing too high?
Simcere Pharmaceutical Group's current Other Financing is HK$-508 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Other Financing compare to ZTS?
Simcere Pharmaceutical Group's Other Financing of HK$-508 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Other Financing is HK$-508 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (HKSE:02096) is currently considered Fairly Valued. The stock's GF Value™ is HK$11.03, compared to a current price of HK$12.14 — trading 10.1% above its estimated fair value. The current Other Financing is HK$-508 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Simcere Pharmaceutical Group (HKSE:02096), the current Other Financing is HK$-508 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (HKSE:02096) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of HK$12.14 is trading 10.1% above its estimated GF Value™ of HK$11.03. GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.

Key valuation signals for HKSE:02096:

  • Other Financing: HK$-508 Mil
  • GF Value™: HK$11.03 vs. price of HK$12.14 (10.1% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the HKSE:02096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges S2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for HKSE:02096

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.14
Price
HK$11.03
GF Value